Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q702 in advanced solid tumors
NCT04648254Phase 1Completed
- Sponsor
- Qurient Co., Ltd.
- Start
- Nov 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adrixetinib in solid tumor, sponsored by Qurient Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicities at 28 days and 1 more. Started Nov 2020; status: completed.
02
Drugs
adrixetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04648254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04648254.